Overview
Lupus anticoagulant is an autoantibody directed against phospholipid-binding proteins that interferes with phospholipid-dependent coagulation reactions. Despite its name, it is not associated with bleeding; instead, it is strongly linked to an increased risk of thrombosis. The term was introduced to describe an inhibitor first identified in patients with systemic lupus erythematosus, although it is now known to occur in individuals without lupus. Lupus anticoagulant acts at the junction of the intrinsic and extrinsic coagulation pathways by impairing activation of prothrombin through interference with the prothrombinase complex. Detection of lupus anticoagulant requires a structured series of laboratory tests rather than a single direct assay.
Symptoms
Lupus anticoagulant itself does not cause specific symptoms but manifests clinically through thrombotic and obstetric complications. Patients may present with unexplained venous or arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction without classic risk factors. In women, recurrent pregnancy loss, preeclampsia, placental insufficiency, and fetal growth restriction are common clinical associations. Some individuals are identified incidentally during the investigation of prolonged clotting times on routine coagulation testing.
Causes
The exact cause of lupus anticoagulant formation remains unclear, though immune dysregulation plays a central role. These antibodies target phospholipids and phospholipid-binding proteins involved in coagulation. Lupus anticoagulant is commonly associated with antiphospholipid syndrome and may occur in autoimmune diseases such as systemic lupus erythematosus. Transient positivity can be seen in infections or following certain medications, while persistent positivity is more strongly linked to thrombotic risk. Genetic predisposition is suspected, but no single trigger has been definitively identified.
Risk Factors
Risk factors associated with lupus anticoagulant include autoimmune disorders, unexplained thrombosis, recurrent miscarriages, and prolonged activated partial thromboplastin time without an identifiable cause. Patients with antiphospholipid syndrome frequently show persistent lupus anticoagulant positivity. Use of anticoagulant therapy, such as heparin or direct oral anticoagulants, can interfere with testing and lead to false positive or false negative results. Coexisting coagulation factor deficiencies or inhibitors must be excluded during evaluation to ensure accurate interpretation.
Prevention
There is no established method to prevent the development of lupus anticoagulant. Prevention of complications relies on early identification and appropriate clinical management. Accurate diagnosis requires a stepwise laboratory approach including screening tests, mixing studies, and confirmatory phospholipid neutralization procedures. Proper sample collection, avoidance of interfering anticoagulant drugs when possible, and repeat testing are essential to distinguish transient from persistent antibodies. Early recognition allows timely risk stratification, guidance for long term anticoagulation, and improved management of thrombotic and pregnancy-related complications.
